Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CEST
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
07/27 Cytokinetics and The ALS Association Renew Partnership to Advance the Fight A..
07/27 CYTOKINETICS INC : Entry into a Material Definitive Agreement (form 8-K)
07/27 Cytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion ..
07/14 Cytokinetics to Announce Second Quarter Results on July 28, 2016
07/05 CYTOKINETICS : to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Con..
07/05 Cytokinetics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare C..
07/01 CYTOKINETICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
06/30 CYTOKINETICS : Announces Start of Phase 2 Clinical Trial of CK-2127107 in Patien..
06/30 Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-2127107 in Pati..
06/15 CYTOKINETICS : to Participate in Upcoming Investor Conferences
More news
Sector news : Bio Therapeutic Drugs
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2016 32,9 M
EBIT 2016 -59,1 M
Net income 2016 -60,0 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 11,9x
Capi. / Sales 2017 14,2x
Capitalization 392 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,2 $
Spread / Average Target 94%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Sharon A. Barbari Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.392
AMGEN, INC.3.29%125 957
GILEAD SCIENCES, INC.-19.90%107 944
CELGENE CORPORATION-11.34%82 247
REGENERON PHARMACEUTIC..-27.26%41 850
VERTEX PHARMACEUTICALS..-24.52%23 493
More Results